Skip to main content

Table 1 Patient and tumor characteristics

From: Favorable safety profile of moderate hypofractionated over normofractionated radiotherapy in breast cancer patients: a multicentric prospective real-life data farming analysis

Characteristics

NFRT (n = 2394)

n (%)

HFRT (n = 1124)

n (%)

Total (n = 3518)

n (%)

Age (years old)

 < 40

181 (7.6)

20 (1.8)

201 (5.7)

 40–50

518 (21.6)

65 (5.8)

583 (16.6)

 50–70

1321 (55.2)

536 (47.7)

1857 (52.8)

 > 70

374 (15.6)

503 (44.7)

877 (24.9)

Performance status

 0

1767 (73.8)

771 (68.6)

2538 (72.1)

 1

569 (23.8)

305 (27.1)

874 (24.8)

 2–3–4

57 (2.4)

48 (4.3)

105 (3)

 NA

1 (0.0)

0 (0.0)

1 (0.0)

Tumor estrogen receptor status

 ER−

368 (15.4)

91 (8.1)

459 (13.0)

 ER+

1612 (67.3)

898 (79.9)

2510 (71.3)

 NA

414 (17.3)

135 (12.0)

549 (15.6)

Tumor progesterone receptor status

 PR−

583 (24.3)

212 (18.9)

795 (22.6)

 PR+

1395 (58.3)

776 (69.0)

2171 (61.7)

 NA

416 (17.4)

136 (12.1)

552 (15.7)

Tumor HER2 status

 HER2−

1659 (69.3)

900 (80.0)

2559 (72.7)

 HER2+

300 (12.5)

77 (6.9)

377 (10.7)

 NA

435 (18.2)

147 (13.1)

582 (16.5)

Tumor grade

 1

335 (14.0)

279 (24.8)

614 (17.5)

 2

873 (36.5)

522 (46.5)

1395 (39.7)

 3

662 (27.6)

158 (14.0)

820 (23.3)

 NA

524 (21.9)

165 (14.7)

689 (19.6)

cT

 T0

121 (5.1)

18 (1.6)

139 (4.0)

 Tis

154 (6.4)

65 (5.8)

219 (6.2)

 T1

1034 (43.2)

732 (65.1)

1766 (50.2)

 T2

682 (28.5)

214 (19.0)

896 (25.5)

 T3

182 (7.6)

35 (3.1)

217 (6.2)

 T4

98 (4.1)

18 (1.6)

116 (3.3)

 NA

123 (5.1)

43 (3.8)

165 (4.7)

cN

 N0

1243(51.9)

905(80.5)

2148 (61.1)

 N1

686 (28.7)

90 (8.0)

776 (22.1)

 N2

172 (7.2)

22 (2.0)

194 (5.5)

 N3

89 (3.7)

18 (1.6)

107 (3)

 NA

204 (8.5)

89 (7.9)

293 (8.3)

cM

 M0

2038 (85.1)

981 (87.3)

3019 (85.8)

 M1

80 (3.4)

28 (2.5)

108 (3.1)

 NA

276 (11.5)

116 (10.2)

391 (11.1)

Histology

 In situ carcinoma

153 (6.4)

79 (7.0)

228 (6.5)

 Invasive ductal carcinoma

1748 (73.0)

821 (73.0)

2572 (73.1)

 Invasive lobular carcinoma

255 (10.7)

121 (10.8)

376 (10.7)

Invasive ductal and lobular carcinoma

134 (5.6)

48 (4.3)

179 (5.1)

 Other

22 (0.9)

20 (1.8)

36 (1.0)

 NA

82 (3.4)

35 (3.1)

127 (3.6)

  1. HFRT : hypofractionated radiotherapy, NFRT :  normofractionated radiotherapy, cTNM : clinical classification for Tumor (T) Node (N) and Metastasis (M) AJCC 7th edition, NA : not available. Estrogen Receptor (ER) and Progesterone Receptor (PR) positive mean more than 10%. Values are number (percentage) unless otherwise specified